A medication used to treat attention deficit/hyperactivity disorder (ADHD) and narcolepsy carries the FDA’s most serious warning, but got recalled for another reason: metal was found embedded in a ...
Methylphenidate hydrochloride extended-release tablets should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and ...
MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and ...
Credit: Alora Pharmaceuticals. Relexxii (methylphenidate hydrochloride extended-release tablets) is now available for the treatment of ADHD in adults and pediatric patients. Relexxii ® ...
(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg ...
Dr. Reddy’s is offering methylphenidate hydrochloride extended-release tablets, in dosage strengths of 18 mg, 27 mg, 36 mg and 54 mg. The product is the generic of Janssen’s Concerta (methylphenidate ...
* Mylan - U.S. launch of methylphenidate hydrochloride extended-release tablets usp, 18 mg, 27 mg, 36 mg and 54 mg, generic version of Janssen's Concerta tablets Source text for Eikon: Further company ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that Quillivant XR™ (methylphenidate hydrochloride) CII for extended-release oral suspension is now available in the U.S. for the ...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results